Court: GSK may have abused sales rules; FDA gives nod to Mylan's generic Risperdal;

> A legal battle between GlaxoSmithKline and Greek wholesalers over parallel trade in drugs--which could have implications for the price of medicine--ended with a mixed result at Europe’s top court. Report

> Mylan said Tuesday the FDA has approved its generic version of the antipsychotic Risperdal, and the company plans to start selling the drug soon. Report

> Haupt Pharma has completed its merger with fellow German companies Amareg and Wülfing Pharma to create a major new force in the European contract development and manufacturing sector. Report

> Pfizer reached a deal to transition some Exubera patients who still need inhaled insulin to MannKind's inhaled insulin product, Technosphere, which recently completed Phase III trials. Pfizer release

> Amylin Pharmaceuticals stock soared more than 4.7 percent yesterday after billionaire investor Carl Icahn increased his stake in the company to 7.33 percent. Report

> Pharmaceutical company Perrigo announced today that it has acquired drug and nutritional products maker JB Laboratories for $44 million. Perrigo release

> After seeing its fortunes rise and fall on the fate of its anemia drugs, Amgen will attempt to turn to a new page with the release of data from 25 studies devoted to its promising osteoporosis drug denosumab. Report

> By injecting stem cells extracted from bone marrow, scientists were able to coordinate the genetic response of animals, dramatically reducing the amount of brain damage triggered by a sudden interruption in the blood supply. Report

> GlaxoSmithKline says it will push pazopanib into late-stage studies for ovarian cancer after a mid-stage trial produced positive data on a key biomarker. Report

> There was a lot of action on the regulatory side of new drug discovery yesterday. We offer a list of the top hits. Report.

> Two top biotech players in Massachusetts are putting a spotlight on a controversial provision of the state's new $1 billion support program for the industry. Report

> France's NicOx has scored an eight percent bump in its stock price with data from a second pivotal trial showing that its leading painkiller hit all three primary endpoints as well as a key secondary endpoint. Report

Emerging Drug Developer: Osprey Pharmaceuticals USA. Report

And Finally... Could thinking make you fat? Maybe. A small Canadian study has found that people eat more after an intellectual exercise than they do after just sitting quietly. Report